CN1839934A - Chinese traditional medicine and its preparation method and use - Google Patents
Chinese traditional medicine and its preparation method and use Download PDFInfo
- Publication number
- CN1839934A CN1839934A CNA2006100420785A CN200610042078A CN1839934A CN 1839934 A CN1839934 A CN 1839934A CN A2006100420785 A CNA2006100420785 A CN A2006100420785A CN 200610042078 A CN200610042078 A CN 200610042078A CN 1839934 A CN1839934 A CN 1839934A
- Authority
- CN
- China
- Prior art keywords
- preparation
- chinese medicine
- medicine
- ethanol
- salviae miltiorrhizae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Disclosed is a Chinese medicament comprising root of red rooted saliva, Japanese yam, Ligusticum wallichii and root of kudzu vine by the weight percents of 10-50%, 5-50%, 5-45%, and 5-45%. Its preparing process comprises the steps of water extraction, filtering, water grilling, passing through macroscopic adsorption resin columns, ethanol washing, collecting the eluent, separating ethanol, concentrating, drying and disintegrating.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof.
Background technology
Cardiovascular and cerebrovascular disease is the commonly encountered diseases of a class serious harm human health and life, has become first cause of death of developed country, and the cardiovascular and cerebrovascular vessel patient of China is also increasing sharply, and cause of the death ranking is forward year by year.The cardiovascular and cerebrovascular disease pilosity is more than 40 years old, and average prevalence is about 10% among this crowd.
The risk factor of cardiovascular and cerebrovascular disease mainly contains hyperlipidemia, hypertension, diabetes, obesity, smoking, shortage motion etc.Coronary artery is atherosis can adopt angioplasty and X-ray therapy in treatment, but adopts angioplasty treatment relapse rate very high, has 1/3 patient accepting this morbidity once more in back 4 months of performing the operation; X-ray therapy is still located the exploratory stage, only adopts in more American-European countries at present.Drug therapy is the main method for the treatment of cardiovascular and cerebrovascular disease at present.Adapt therewith, the cardio-cerebralvascular medicine is a domestic and international class medicine with the fastest developing speed, the first place that sales volume occupies world's pharmaceutical market always since the last century late nineteen eighties, and portion is up to 22%.At present the treatment treating coronary heart disease and angina pectoris kind of using clinically is many really, chemical medicine such as nitrate esters, calcium antagonist class and beta-blocker etc., though these medicines have rapid-action speciality, side effect is many and be by force deadly defect.The toleration of Chinese patent medicine is better, but present most Chinese patent medicine exists dose big, shortcomings such as curative effect shakiness.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine and preparation method thereof and its application in the medicine of preparation treatment cardiovascular and cerebrovascular disease, to remedy the above-mentioned deficiency of prior art.
A kind of Chinese medicine is characterized in that being made up of Radix Salviae Miltiorrhizae, Rhizoma Dioscoreae Nipponicae, Rhizoma Chuanxiong, Radix Puerariae, and their percetage by weight scope is respectively: 10～50%, 5～50%, 5～45%, 5～45%.
Above-mentioned preparation method of Chinese medicine is characterized in that taking by weighing respectively Radix Salviae Miltiorrhizae, Rhizoma Dioscoreae Nipponicae, Rhizoma Chuanxiong, Radix Puerariae; Use water extraction Radix Salviae Miltiorrhizae and Radix Puerariae down at 20 ℃～80 ℃ earlier, filter, get filtrate A; Reuse water boiling and extraction Rhizoma Dioscoreae Nipponicae and Rhizoma Chuanxiong filter, and get liquor B; Liquor B and filtrate A are merged, by macroporous adsorptive resins, wash with water earlier to the Molish reaction and be negative, it is colourless that reuse ethanol or aquiferous ethanol are washed till effluent, collects eluent, tells ethanol, and concentrate drying is pulverized.
The application of above-mentioned Chinese medicine in the medicine of preparation treatment cardiovascular and cerebrovascular disease.
Medicine of the present invention have blood stasis dispelling promote blood circulation, eliminate the phlegm promote the production of body fluid, the effect of promoting the circulation of QI to relieve pain; can dilating coronary blood vessel, reduce myocardial oxygen consumption, thrombus, improve myocardial ischemia and microcirculation, improve blood vessel inner skin cell function, cerebral blood flow increasing, damage has protective effect to the ischemic brain cell; can also bring high blood pressure down, blood fat, blood glucose, thereby reach the purpose of treatment cardiovascular and cerebrovascular disease.Efficacy of drugs of the present invention is obvious, and toxic and side effects is little, taking convenience, and steady quality is reliable, has good clinical and promotes the use value.
The specific embodiment
Embodiment 1: the preparation of medicament capsule of the present invention
Take by weighing Radix Salviae Miltiorrhizae 3000g, Rhizoma Dioscoreae Nipponicae 2750g, Rhizoma Chuanxiong 2000g, Radix Puerariae 1250g; Wherein Radix Salviae Miltiorrhizae and Radix Puerariae are put together with 60 ℃ flooding 2 times, and the weight of each institute water is Radix Salviae Miltiorrhizae and Radix Puerariae gross weight 8 times, and each lixiviate 2 hours is filtered, filtrate A; All the other two kinds of medical material water reflux, extract, 3 times, the weight of each institute water are 10 times of two kinds of medical material gross weights, and each lixiviate 1.5 hours is filtered, and gets liquor B; Liquor B and filtrate A are merged, by AB-8 type macroporous adsorptive resins, wash with water earlier to the Molish reaction and be negative, it is colourless that reuse ethanol or aquiferous ethanol are washed till effluent, collect eluent, tell ethanol, concentrate drying, pulverize, cross sieve No. 5, promptly get Chinese medicine of the present invention.In the medicine, add 300g starch (adjuvant) hereinto, mixing, 3000 of capsules are made in packing.Every capsules is equivalent to crude drug in whole 3g.
Embodiment 2: the preparation of medicinal dropping ball of the present invention
Take by weighing Radix Salviae Miltiorrhizae 2750g, Rhizoma Dioscoreae Nipponicae 3000g, Rhizoma Chuanxiong 1750g, Radix Puerariae 1500g; Wherein Radix Salviae Miltiorrhizae and Radix Puerariae are with 80 ℃ flooding 2 times, and the weight of each institute water is Radix Salviae Miltiorrhizae and Radix Puerariae gross weight 10 times, and each lixiviate 1.5 hours filters, filtrate A; All the other two kinds of medical material water reflux, extract, 3 times, the weight of each institute water are 8 times of two kinds of medical material gross weights, each 1 hour, filter, and get liquor B; Liquor B and filtrate A are merged, pass through HPD
100The type macroporous adsorptive resins washes with water earlier to Molish reaction and is negative, and it is colourless that reuse ethanol or aquiferous ethanol are washed till effluent, collects eluent, tells ethanol, and concentrate drying is pulverized, and promptly gets Chinese medicine of the present invention.In the medicine, add 150 gram propylene glycol hereinto, mixing, adding 450 restrains the polyethylene glycol 6000 of melting, adds the relaxing the bowels with purgatives of warm nature mixing at 80 ℃, splashes in the methyl-silicone oil, makes 30,000 of drop pill.Every drop pill is equivalent to crude drug in whole 0.3g.
In the above-mentioned preparation method, the extracting method of described Radix Salviae Miltiorrhizae, Radix Puerariae is lixiviate, and extraction time can be 1～3 time, and extraction time can be 0.5～2 hour, and water temperature raising degree can be 20～80 ℃, and amount of water can be 4～16 times of two kinds of medical material gross weights; Described all the other two kinds of medicinal material extract number of times can be 1～3 time, and extraction time can be 0.5～2 hour, and amount of water can be 4～16 times of two kinds of medical material gross weights; That described macroporous adsorbent resin can be is nonpolar, low pole or polar resin; The concentration of described eluent ethanol water can be 30～95%; Described adjuvant is for example starch, lactose, micropowder silica gel, Pulvis Talci, propylene glycol, a Polyethylene Glycol etc. of acceptable accessories, Chinese medicine of the present invention can be made multiple dosage form, for example is prepared into oral tablet, capsule, drop pill or oral liquid.
Medicine by above method preparation, after testing, wherein the salvianolic acid B rate of transform is 83.3%, the rate of transform of puerarin is 81.5%, and the rate of transform of ferulic acid is 95.2%, and paste-forming rate is reduced to below 4% by 33.7%, show that this preparation technology is scientific and reasonable, keep main effective ingredient in the medicine, significantly reduced dose simultaneously, reached purified purpose.
Below prove the beneficial effect of Chinese medicine of the present invention by pharmacodynamics test.
Test example 1: the influence of the Acute Myocardial Ischemia in Rats that medicine of the present invention causes the ligation coronary artery
Confirm that by pharmacological testing contrast medicine of the present invention is used for cardiovascular and cerebrovascular disease and has significant pharmacologically active with FUFANG DANSHEN DIWAN.
1. test material
Medicine: press the medicament capsule of embodiment 1 method preparation, hereinafter to be referred as the HDN capsule, the 0.2g/ grain is equivalent to crude drug in whole 3g, and promptly every gram capsule medicated powder is equivalent to crude drug in whole 15 grams.Press the medicinal dropping ball of embodiment 2 methods preparation, hereinafter to be referred as the HND drop pill, the 30mg/ grain is equivalent to crude drug in whole 0.3g, and promptly every gram drop pill is equivalent to crude drug in whole 10 grams.The positive drug FUFANG DANSHEN DIWAN, 27mg/ ball, 150 ball/bottles, Tianjin Tasly Pharmaceutical Co., Ltd, lot number 20041009.
Reagent: RT nitrogen (TTC), Amresco import packing, lot number 2803B19, face with preceding be 7.4 PBS (concentration expressed in percentage by weight, the down with) concentration that is assigned to 1% with pH, keep in Dark Place.
Instrument and apparatus: 5/0 swaged needle, Shanghai Medical Sewing Needle Factory, lot number W-0404-2.The ALC-V8 animal respirator, Shanghai Alcott bio tech ltd.The ECG-6511 electrocardiograph, ShanghaiKOHDEN Medical Electronic Instrument Corporation.
Animal: 40 of SD rats, male, body weight 250-300g, cleaning level is provided by west, Shanghai pul-Bi Kai laboratory animal company limited, the animal quality certification number: SCXK (Shanghai) 2003-0002.
2. dosage setting and medication
Test is established 4 groups altogether, be respectively model group (0.5% CMC-Na, 10ml/kg), Composite Salvia Dropping Pill group (500mg/kg), HDN (200mg/kg) Capsules group and HDN (400mg/kg) drop pill group, every group of 10 animals, each dosage group medicine all grinds evenly with 0.5% CMC-Na, is assigned to respective concentration, and the administration volume is 10ml/kg, in every morning gastric infusion once, continuous 7 days.
3. the rat heart muscle ischemia model is set up
Each treated animal is 30min after last 1 administration, anaesthetize with urethane (110g/kg) ip, fixing, connect animal respirator, monitor electrocardiogram (limbs II leads) simultaneously, open breast through left border of sternum, expose heart, tear pericardium, under the Coronary vein between pulmonary conus and left auricle, with 5/0 swaged needle ligation left coronary artery, significantly raise as ligation success index with ECG T wave, close tight thoracic cavity (draining air in the thoracic cavity), the stable breathing about about 10min removed respirator and recovered autonomous respiration.Behind the ligation 4h, put to death animal, take out heart dyeing, carry out ischemic areas and measure.
4. the mensuration of ischemic areas
Take out rat heart, remove the atrium, ventricle is cleaned behind the blood behind-20 ℃ of freezing 10min with normal saline, free-hand blade is cut into the myocardium sheet of 1～2mm, place the 1%TTC solution of pH7.4PBS preparation, 37 ℃ of incubation 10min dyeing, normal cardiac muscle is dyed and is peony on the myocardium sheet, and ischemic myocardium is canescence.Normal and the ischemia part cardiac muscle of will dyeing on the myocardium sheet in back is weighed respectively, with the ratio of the myocardium shared whole ventricular muscles weight of ischemia part as the ischemia index.
5. date processing and statistical method
Each is organized data and all represents with x ± s, relatively adopts the t check to investigate significance between group, with P＜0.05 as significant indexes.
6. result
The results are shown in Table 1.Model group animal ischemia part cardiac muscle is 34.5%, and FUFANG DANSHEN DIWAN 500mg/kg all can make ischemic areas obviously dwindle, and the ischemic region ratio is 26.7% (P＜0.05).HDN capsule 200mg/kg, HND drop pill 300mg/kg also can significantly reduce ischemic areas, and the ischemic region ratio is respectively 25.8% and 25.2% (P＜0.01).
The influence of the Acute Myocardial Ischemia in Rats area that table 1. Chinese medicine of the present invention causes the ligation coronary artery (n=10, x ± s)
| Group | Dosage (mg/kg) | Ischemic region cardiac muscle weight (g) | Ventricular muscles gross weight (g) | The ratio (%) that ischemic region is shared |
| Model group FUFANG DANSHEN DIWAN HDN capsule HDN drop pill | 500 200 300 | 0.271±0.062 0.202±0.028 0.199±0.029 0.195±0.012 | 0.793±0.065 0.756±0.053 0.769±0.036 0.775±0.047 | 34.5±8.8 26.7±2.6 * 25.8±3.1 ** 25.2±1.8 ** |
*P＜0.05,
*P＜0.01 is compared with model group.
By above-mentioned pharmacodynamics test, prove absolutely that treatment by Chinese herbs cardiovascular and cerebrovascular disease of the present invention is evident in efficacy, provide a kind of new medication to select for clinical.Medicine of the present invention can be used to prepare treatment coronary heart disease, angina pectoris, heart failure, arrhythmia, cerebral infarction, cerebral ischemia, medicine that arteries is atherosis, all can obtain similar good effect.
Claims (5)
1. a Chinese medicine is characterized in that being made up of Radix Salviae Miltiorrhizae, Rhizoma Dioscoreae Nipponicae, Rhizoma Chuanxiong, Radix Puerariae, and their percetage by weight scope is respectively: 10～50%, 5～50%, 5～45%, 5～45%.
2. the application of the described Chinese medicine of claim 1 in the medicine of preparation treatment cardiovascular and cerebrovascular disease.
3. application as claimed in claim 2 is characterized in that described cardiovascular and cerebrovascular disease is that coronary heart disease, angina pectoris, myocardial ischemia, heart failure, arrhythmia, cerebral infarction, cerebral ischemia or arteries are atherosis.
4. the described preparation method of Chinese medicine of claim 1 is characterized in that taking by weighing respectively Radix Salviae Miltiorrhizae, Rhizoma Dioscoreae Nipponicae, Rhizoma Chuanxiong, Radix Puerariae; Use water extraction Radix Salviae Miltiorrhizae and Radix Puerariae down at 20 ℃～80 ℃ earlier, filter, get filtrate A; Reuse water boiling and extraction Rhizoma Dioscoreae Nipponicae and Rhizoma Chuanxiong filter, and get liquor B; Liquor B and filtrate A are merged, by macroporous adsorptive resins, wash with water earlier to the Molish reaction and be negative, it is colourless that reuse ethanol or aquiferous ethanol are washed till effluent, collects eluent, tells ethanol, and concentrate drying is pulverized.
5. preparation method of Chinese medicine as claimed in claim 4 is characterized in that making after the described Chinese medicine, adds carrier or adjuvant, and preparation becomes oral tablet, capsule, drop pill or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100420785A CN100377731C (en) | 2006-01-14 | 2006-01-14 | Chinese traditional medicine and its preparation method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100420785A CN100377731C (en) | 2006-01-14 | 2006-01-14 | Chinese traditional medicine and its preparation method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1839934A true CN1839934A (en) | 2006-10-04 |
| CN100377731C CN100377731C (en) | 2008-04-02 |
Family
ID=37029237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100420785A Expired - Fee Related CN100377731C (en) | 2006-01-14 | 2006-01-14 | Chinese traditional medicine and its preparation method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100377731C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103584098A (en) * | 2013-11-16 | 2014-02-19 | 丽江玛咖生物科技有限公司 | Maca almond tablet and preparation method thereof |
| CN103948783A (en) * | 2014-04-30 | 2014-07-30 | 王莉 | Pharmaceutical composition for preventing and/or treating cerebral infarction |
| CN104586928A (en) * | 2014-12-29 | 2015-05-06 | 长顺县文会虫草种植有限公司 | Traditional Chinese medicine for treating hypertension and hyperglycemia |
| CN106361811A (en) * | 2016-09-21 | 2017-02-01 | 神威药业集团有限公司 | Tongmai pharmaceutical composition and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1356113A (en) * | 2000-11-28 | 2002-07-03 | 袁曙光 | Process for preparing Chinese medicine to treat cardiovascular and cerebrovascular diseases |
-
2006
- 2006-01-14 CN CNB2006100420785A patent/CN100377731C/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103584098A (en) * | 2013-11-16 | 2014-02-19 | 丽江玛咖生物科技有限公司 | Maca almond tablet and preparation method thereof |
| CN103584098B (en) * | 2013-11-16 | 2016-01-27 | 丽江玛咖生物科技有限公司 | Maca almond tablet and preparation method thereof |
| CN103948783A (en) * | 2014-04-30 | 2014-07-30 | 王莉 | Pharmaceutical composition for preventing and/or treating cerebral infarction |
| CN104586928A (en) * | 2014-12-29 | 2015-05-06 | 长顺县文会虫草种植有限公司 | Traditional Chinese medicine for treating hypertension and hyperglycemia |
| CN104586928B (en) * | 2014-12-29 | 2018-10-23 | 长顺县文会虫草种植有限公司 | Treat the Chinese medicine of hypertension, hyperglycemia |
| CN106361811A (en) * | 2016-09-21 | 2017-02-01 | 神威药业集团有限公司 | Tongmai pharmaceutical composition and preparation method thereof |
| CN106361811B (en) * | 2016-09-21 | 2019-11-22 | 神威药业集团有限公司 | One kind is promoted blood circulation pharmaceutical composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100377731C (en) | 2008-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1895620A (en) | Chinese-medicinal composition for treating coronary heart disease | |
| CN101433689A (en) | Kudzu root and longstamen onion bulb oral liquid and preparation method | |
| CN100377731C (en) | Chinese traditional medicine and its preparation method and use | |
| CN101306138B (en) | Chinese traditional injection preparation for treating chest stuffiness and pains and its preparation method | |
| CN101716248B (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN101152223B (en) | Use of poplar leaf phenols extract in preparation of medicine for treating cardiovascular disease | |
| CN105998752B (en) | A kind of Chinese medicine composition for the treatment of of vascular dementia | |
| CN1262942A (en) | Intravenous injection medicine for curing ischemic cerebrovascular disease and its preparing method | |
| CN1927289A (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and its preparation | |
| CN110292607A (en) | The Chinese medicine composition and preparation method for treating the concurrent left ventricular hypertrophy of high blood pressure | |
| CN1182862C (en) | Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn | |
| CN100384439C (en) | Medicinal composition for treating and/or preventing heart brnin blood vessel disease and its preparation method | |
| CN107158268A (en) | It is a kind of to treat Chinese medicine composition of hypertension and its preparation method and application | |
| CN1943710A (en) | The application of radix ophioponis in the medicines for treating myocarditis and medicines containing its extracts with active elements | |
| CN1290530C (en) | Fumaiding Chinese medicinal preparation for treating arrhythmia and its preparation method | |
| CN107536938A (en) | A kind of vital energy regualting and blood circulation-promoting preparation is preparing the application in treating or preventing renal damage medicine | |
| CN101129604A (en) | Antihypelipidemic traditional Chinese medicine and method of producing the same | |
| CN1853711A (en) | Xinmaikangzhong Chinese medicinal composition and preparation thereof | |
| CN105267470B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating coronary heart disease | |
| CN1245180C (en) | Hypertension treating traditional Chinese medicine preparation and its preparing process | |
| CN1267126C (en) | Chinese medicine for treating coronary heart disease and angina pectoris | |
| CN104940554A (en) | Chinese herbal composition for treating heart diseases | |
| CN1899338A (en) | Chinese medicine composition for supplementing qi and promoting blood circulation | |
| CN1650962A (en) | Chinese medicinal preparation for treating arrhythmia and its preparation method | |
| CN101396521B (en) | Use of traditional Chinese medicine composition in preparing medicine for treating cerebral circulation insufficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 266000 Qingdao, Shandong Province, Qingdao City, Pingdu City, New River ecological chemical technology industry base, No. 6 Patentee after: Haopu Medicine Research Co., Ltd., Qingdao Address before: 266111 Shandong Province, Qingdao city Chengyang District Green Industrial Park Patentee before: Haopu Medicine Research Co., Ltd., Qingdao |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080402 Termination date: 20200114 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |